Stemtech Corporation announced a significant milestone in its global expansion strategy with the signing of a license Agreement with an established direct sales company, based in Kenya. The Agreement, effective January 29, 2024, grants the license to purchase, use, market, and distribute Stemtech's cutting-edge health related products within the designated Territory(s), including Kenya, Uganda, Tanzania, Ghana, Democratic Republic of Congo and Nigeria. This strategic move represents Stemtech's commitment to reaching new markets and introducing its patented stem cell nutrition, skin care and oral care products to new markets.

The licensing agreement includes the distribution of StemRelease3, StemFlo Advanced, MigraStem, OraStem, and Cellect Onetm Rapid Renew Stem Cell Peptide Night Cream. Additionally, the new Licensee has already placed a significant initial order, and Stemtech Corporation has received certified funds for these products. This financial commitment underscores the confidence both parties have in the success of this venture.

The licensing agreement is structured for a twenty-four (24) month term, during which the new distributor will serve as the exclusive Stemtech representative for the specified products in the agreed-upon Territory(s). The Agreement includes provisions for annual sales volumes, product pricing, and compliance with applicable laws. Stemtech Corporation looks forward to a successful collaboration within Africa and anticipates mutual growth and success as they work together to bring Stemtech's innovative products to new African markets.